Back

Long-term safety and efficacy of aficamten in the evolving era of myosin inhibition for obstructive hypertrophic cardiomyopathy

European Heart Journal

6 March 2026
Organised by: Logo
Read full article
ESC Journals VALVULAR, MYOCARDIAL, PERICARDIAL, PULMONARY, CONGENITAL HEART DISEASE Myocardial Disease

Contributors

Luis R Lopes
Luis R Lopes

Author

You may be interested in
thumbnail
Congress Presentation
The evolution of the obstructive HCM therapeutic landscape: emerging evidence about cardiac myosin inhibitors
31 August 2025
thumbnail
Congress Presentation
The evolving role of cardiac myosin inhibitors in obstructive HCM
31 August 2025
thumbnail
Congress Presentation
Estimation of the target population of a selective cardiac myosin inhibitor for hypertrophic obstructive cardiomyopathy: Real-life data from the French REMY register.
22 May 2023
thumbnail
Congress Presentation
Long-term safety and effectiveness of mavacamten in symptomatic obstructive hypertrophic cardiomyopathy (oHCM) patients (pts): update from PIONEER open-label extension (PIONEER-OLE) study
31 August 2019

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources